Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05280586 vs Rituximab in Follicular Lymphoma
NCT02213263Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Pfizer. Primary endpoint: Overall Response Rate at 26 weeks. Started Sep 2014; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02213263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02213263.